Infigratinib

5 trials 3 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

7 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 3

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Hypochondroplasia 2

Sponsors using this IMP

Qed Therapeutics Inc. 5

All trials

5 total

Open-Label, Long-Term, Extension Study of Infigratinib in Children with Hypochondroplasia Pending

2025-523509-13-00 Phase II 2 countries Qed Therapeutics Inc.
A study to investigate the safety and efficacy of infigratinib compared with placebo in infants and young children with achondroplasia Recruiting

2024-518072-31-00 Phase II 2 countries Qed Therapeutics Inc.
Open-Label followed by a Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with Hypo… Recruiting

2024-516822-67-00 Phase II/III 5 countries Qed Therapeutics Inc.
A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting

2024-513857-55-00 Phase II 4 countries Qed Therapeutics Inc.
A Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with Achondroplasia Ended

2023-506130-67-00 Phase III 5 countries QED Therapeutics Inc.

Showing 1–5 of 5 trials

← All drugs A–Z